The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
|Articles|June 25, 2015
Outlook: Market Access in Australia
Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.
Advertisement
Australia is a country that has challenged pharmaceutical manufacturers in recent years with extensive government reforms in drug pricing, unpredictability around reimbursement and pricing decisions, and other structural changes. Despite these challenges, the Australian market still offers a number of opportunities for manufacturers.
This
Advertisement
Related to this article
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
4
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
5